return icon

Foreign investors continue to target Vietnam’s pharmaceutical industry

Vietnam's pharmaceutical market has a lot of potential coming from the demographics, rising income and priority policies of the government.

Foreign investors would continue to target Vietnam’s pharmaceutical industry following deals such as DHG Pharmaceutical with Taisho Pharmaceutical (Japan), Mekophar Pharmaceutical with Nipro Pharma Corporation (Japan), Pymepharco with Stada (Germany), or Domesco Medical Import-Export with Abbott (US), according to Viet Dragon Securities Company (VDSC).

As the pharmaceutical industry remains undeveloped in Vietnam, local companies want to find a foreign partner who can transfer production technology and solve output problems through drug export. On the other hand, Vietnamese firms are attractive by the low production costs and the potential domestic market, stated VDSC’s latest report.


A study from the United Nations Population Fund (UNFPA) suggested although Vietnam is still a young country, the population entered the "aging phase” in 2017. Meanwhile, a report from the World Bank warned that population aging will likely hit Vietnam with full force within a very short span of time. This transition could come in a mere 15 years and be completed well before the 2040s. An aging population means more spending on pensions and healthcare.

In 2019, sales of Vietnam's pharmaceutical market are estimated at US$6.5 billion, of which hospital channel sales account for 75%. In addition, VDSC expected the government will have to increase spending on health care in the coming years. That was what took place in China, and it is likely to happen in Vietnam. This means that pharmaceutical companies focusing on the hospital channel will benefit.

Moreover, rising health care spending is only a matter of time. It requires the government to control expenditure better, and also to control inflation. Therefore, reducing costs and improving efficiency in health facilities is an inevitable trend. One such solution is to encourage health facilities to use domestic drugs instead of imported ones, through policies that the government has been implementing.

Challenges remain

Currently, domestic companies are not capable of pursuing the research and development of patent drugs and can only manufacture generic drugs. However, even in the generic drug segment, Vietnamese medicine only meets about 40% of the domestic demand. The reason is that most national manufacturers only have WHO-GMP standards and can only produce medium-low quality generic drugs.


Meanwhile, high quality generic drugs (which can bid for Tier 1 and 2 in hospital channels) require manufacturers to have EU-GMP or PIC/S-GMP standards - currently only 17 facilities meet either one of these two standards, besides 222 WHO-GMP standard facilities. Among the listed companies, only Pymepharco and Imexpharm are capable of bidding into Tier 1 and 2 due to having EU-GMP standard factories.

There are more than 90% of drug materials using in the industry still being imported, of which about half  from China. In addition to exchange rate risk, especially the USD/VND and USD/CNY pairs, raw materials price from China has also skyrocketed in the last two years due to the closure of many factories in China, as an attempt to protect the environment. This has a negative impact on the profit margins of most Vietnamese pharmaceutical companies because medicines price is under the government’s control and the fierce competition in the industry makes it almost impossible to pass increasing cost to consumers.

VDSC’s report suggested the Vietnamese pharmaceutical market has a lot of potential coming from the demographics, rising income and priority policies of the government, however, as with any development of other industries, after the fragmented phase will be the competitive and selective one.

“The end goal is for consumers to use medicines with high quality standards and reasonable prices,” stated the report. Hanoitimes

Ngoc Thuy

VN's pharmaceutical import turnover may reach $3 billion by end of year

VN's pharmaceutical import turnover may reach $3 billion by end of year

With the average pharmaceutical import turnover of $245 million per month, the figure of the whole year of 2019 may reach $3 billion, equaling 50 per cent of the whole scale of the market.  

Vietnam emerges as a global pharmaceutical hub

Vietnam emerges as a global pharmaceutical hub

According to experts, the boost in attractiveness of the Vietnamese market comes at a time when the business environment for drugmakers in neighboring countries has not been favorable.


Aviation ground services to go-green to meet compliance

The Civil Aviation Authority of Vietnam (CAAV) is collecting comments on a draft circular stipulating that all businesses in the sector must have a plan to convert ground vehicles from fossil fuels to electric.

President visits, offers condolences to widow of late PM Abe Shinzo

President Nguyen Xuan Phuc visited and offered condolences to Abe Akie, the widow of late Japanese Prime Minister Abe Shinzo, at her home on September 28.


US firm pours capital in cross-border e-commerce project in Binh Duong


PM requests prompt measures to overcome Typhoon Noru’s consequences

Dim outlook for domestic auto component industry

Vietnamese automotive component industry has a dim outlook for growth as it lags behind those in many other regional countries, according to the Ministry of Industry and Trade (MoIT).

Animated series seeks to change stereotypes on Vietnamese products

Wolfoo, a YouTube children’s animated web series, which has reached more than 2 billion views a month, has changed the world’s stereotypes on Vietnamese products.

VN banking prospects from now to the end of the year

Under the circular, the State Bank of Vietnam told banks to reschedule debt repayments to help customers affected by the COVID-19 pandemic until June 30 this year.

JPMorgan: 65% of AirPods production to be located in Vietnam in 2025

JPMorgan analyst expects 20 percent of iPad, 5 percent of MacBook, 20 percent of Apple Watch and 65 percent of AirPods production to be located in Vietnam in 2025.

US$2.3 billion withdrawn from stock market, investors begin to worry

Concerns are increasing in the stock market after the State Bank of Vietnam (SBV) raised regulating interest rates and withdrew VND56 trillion (over US$2.3 billion) last week.

Teacher Nguyen Ngoc Ky writing with feet passes away

This morning, 75-year-old teacher Nguyen Ngoc K, who inspired many generations of students with his determination to rise up in life, passed away at his home in Thu Duc City.

Typhoon Noru passes through central Vietnam

Super typhoon Noru swept through central Vietnam on September 27 night and early September 28, bringing strong winds and torrential rains.

Discovering craft villages in Buddhist centre in Quang Ninh

Coming to Yen Tu relic site in Quang Ninh province – Vietnam’s major Buddhist centre, tourists can also experience traditional crafts such as making hats, bamboo handicrafts, and wood carvings.

Ministry drafts mechanism to adjust average retail power price

The Ministry of Industry and Trade (MoIT) is drafting a Prime Minister's Decision on the mechanism for adjusting the average retail electricity price.

Foreign investment disbursement hits record high in nine months

Disbursement of foreign direct investment (FDI) in the first nine months of this year reached 15.4 billion USD, up 16.2 % year-on-year and marking a record high, a report from the Foreign Investment Department (FIA) has shown.

Foreign Minister Bui Thanh Son pays visit to Germany

Minister of Foreign Affairs Bui Thanh Son paid an official visit to Germany from September 26-27 at the invitation of his German counterpart Annalena Baerbock.